◆NTRK fusions are extremely rare in colorectal carcinomas. The overall incidence is approximately 0.35% in a cohort of 2314 colorectal carcinomas, with NTRK fusions confined to those tumors that are pan-wild type KR...
Primary tumor location is an important predictive factor for wild- type KRAS metastatic colon cancer treated with cetuximab as front-line bio-therapy. Asia Pac J Clin Oncol 2016;12(3):207e15.Lu HJ, Lin JK, Chen WS, Jiang JK, Yang SH, Lan YT, Lin CC, Chang SC, Teng HW. Primary ...
1. Muzny DM, et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012 Jul 18;487(7407):330-7. 2. Cervantes A, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guide...
Colorectal cancer (CRC) is among the most commonly diagnosed cancers affecting both genders in the world. It is characterized by genetic instability, which drives tumor formation via the activation of oncogenes, such as KRAS and B-RAF. Approximately 40%
Although the discovery of KRAS mutations has improved patient selection for EGFR-targeted treatments, further biomarkers are required, especially for those patients who exhibit KRAS mutations rather than the wild-type gene. Keywords: EGFR, colorectal cancer, predictive biomarker, KRAS 展开 ...
Inhibitors of the epidermal growth factor (EGFR) signaling pathway have a major role in the treatment of KRAS wild-type colorectal cancer patients. The EGFR pathway has been shown to be activated in gastric cancer (GC). However, published data on KRAS and BRAF mutation status is limited in ...
Question Does the addition of cetuximab with a combination chemotherapeutic regimen improve overall survival compared with the addition of bevacizumab with a combination chemotherapeutic regimen as the initial treatment for patients with advanced or metastatic colorectal cancer who have KRAS wild-type tumors...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity...
[4]Bokemeyer C,Van Cutsem E,Rougier P,et al.Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer:pooled analysis of the CRYSTAL and OPUS randomised clinical trials[J].Eur J Cancer,2012,48(10):1466-1475. [5] Bokemeyer C,Bondarenko...
Our findings indicate that bromelain effectively exerts cytotoxic effects in Kras mutant colorectal cancer cells compared to in Kras wild-type colorectal cancer cells. Differential expression of ACSL-4 is responsible for the differential action of bromelain in regulating ferroptotic cell death....